Novo Nordisk vs. Pfizer: Does a Weight Loss or Cancer Focused Pharma Stock Make a Better Buy for 2027?

From The Motley Fool 14 Nov 2026, 17:12 UTC 1 min read

Novo Nordisk's obesity-drug dominance faces rising rivals, while Pfizer's cheaper valuation and cash flow tell a different story for income-minded investors.

Full story

Continue reading this story on The Motley Fool, the publisher that reported it.

Read the full story at The Motley Fool ↗

AI tools

Written by AI from the article text. It can make mistakes; check the original story.

News

Business

National

Discover

Novo Nordisk vs. Pfizer: Does a Weight Loss or Cancer Focused Pharma Stock Make a Better Buy for 2027?

AI tools

Topics in this story

More from Business

Nvidia's leadership crisis rattles the AI trade. Here's how we're adjusting our portfolio

STMicro: 3 Key Takeaways for Long-Term Investors

Sandisk’s Stock Split Takes Effect Nov. 19. Should You Buy It Now?

Allegro: 3 Key Takeaways for Long-Term Investors

Bill Ackman Says Freeing Fannie Mae and Freddie Mac From Government Control Could Unlock $500 Billion in Value, Just as Both Stocks Have Jumped Over 23% in the Past Month. Is Now the Time to Bet on That Payoff?

Accenture vs. Adobe: Which Technology Stock Is a Better Buy for 2027?